Oral Mucositis Om Market

DelveInsight’s ‘Oral Mucositis Market Insights, Epidemiology, and Market Forecast —2030’ report delivers an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology as well as the Oral Mucositis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Oral Mucositis market report provides current treatment practices, emerging drugs, Oral Mucositis market share of the individual therapies, current and forecasted Oral Mucositis market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Oral Mucositis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Oral Mucositis (OM): Disease Understanding and Treatment Algorithm

Oral Mucositis Overview

Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastrointestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. The mucosa is the thin outer layer that lines most organs including the mouth, throat, esophagus, stomach, and bowel that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis. Oral mucositis refers to the oral erythematous and ulcerative lesions commonly observed in patients undergoing cancer therapy. They are painful and affect nutrition and contribute to local and systemic infections.


Oral Mucositis Diagnosis

Clinical signs of mucosal damage and cell death appear after the first 1–2 weeks of radiation therapy and as early as 3 days after chemotherapy. Initial mucosal damage results in patchy erythema, edema, atrophy, and whitening of the mucosal tissue with increased sensitivity—patients report a burning sensation in the mouth. Further loss of mucosal epithelium becomes most prominent in the fourth or fifth week of standard fractionation radiation resulting in fibrinous exudation, confluent inflammation, and ulceration. The mouth sores and swelling can lead to significant oral pain, pain with swallowing, weight loss, and dehydration. Mucosal damage predisposes the patient to oral-super infection leading to further pain and alterations in taste and appetite and decreased quality of life. 


Diagnosis is based on the symptoms the patient is experiencing and the appearance of the tissues of the mouth following chemotherapy, bone marrow transplants, or radiotherapy. Red burn-like sores or ulcers throughout the mouth is enough to diagnose mucositis. Oral mucositis is typically diagnosed based on the appearance, location, and timing of oral lesions, as well as the medical history, which may show a medication or treatment form that is highly linked with Oral Mucositis.


Useful laboratory tests for confirming diagnosis and etiology, especially if local fungal, bacterial, or viral infections infection is suspected, are complete blood count, Viral Culture, biopsy, and fungal testing. A wide variety of scales have been used to record the extent and severity of oral mucositis in clinical practice and research. The most commonly used scales are World Health Organization (WHO) Oral Toxicity score, The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Radiation Therapy Oncology Group (RTOG) Scale, and Oral assessment guide for children & young people.


Oral Mucositis Treatment

Currently, several treatment options are used to prevent or treat mucositis. The interventions include general oral care protocols; interventions to reduce the mucosal toxicity of chemotherapy drugs; mouthwashes with mixed action; immunomodulatory agents; topical anesthetics; antiseptics; mucosal barriers and coating agents; cytoprotectants; mucosal cell stimulants; psychotherapy; and analgesics. Kepivance (palifermin) is the first therapy approved to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.


Other oral rinse and devices approved for reducing the symptoms of Oral Mucositis are MuGard (Access Pharmaceuticals), Chemo Mouthpiece (Aurora BioScience), and Episil (Camurus).  

Oral Mucositis Epidemiology

The Oral Mucositis epidemiology division provides the insights about historical and current Oral Mucositis patient pool and forecasted trends for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted Oral Mucositis epidemiology segmented as [Total Incident Cases of Oral Mucositis, Grade-specific cases of Oral Mucositis, and Treated cases of Oral Mucositis] scenario of OM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030. 

Country Wise- Oral Mucositis Epidemiology

  • Estimates show that the highest incident cases of Oral Mucositis in the 7MM were in the United States, followed by Japan in 2020.
  • The United States, in 2020, accounted for 596,671, Oral Mucositis incident cases, which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total incident cases of Oral Mucositis in EU5 were 623,424, which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total incident cases of Oral Mucositis in Japan were 260,358, which are expected to grow during the study period, i.e., 2018–2030.

Oral Mucositis Drug Chapters

The drug chapter segment of the OM report encloses the detailed analysis of OM marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the OM clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Oral Mucositis Approved Drugs/Devices


Kepivance/palifermin (Amgen/ Swedish Orphan Biovitrum)

Kepivance (palifermin) is a truncated human keratinocyte growth factor (KGF) produced by recombinant DNA technology in E coli. It is a medicine indicated for the prevention and treatment of severe oral mucositis (mouth sores). It is used in patients with certain forms of blood cancer who are undergoing high-dose chemotherapy accompanied by a stem cell transplant and radiation therapy. The prevention and treatment of common side effects of other cancer types are also being studied.


MuGard (Access Pharmaceuticals (now Abeona Therapeutics)

MuGard is a mucoadhesive oral wound rinse Rinse is a viscous hydrogel polymer solution that is dispensed in a ready-to-use form. This device is supplied in plastic bottles is intended for the treatment of oral wounds such as mucositis, stomatitis, traumatic ulcers, and aphthous ulcers. The mucoadhesive formulation results in the development of a protective coating over the oral mucosa when swirled carefully across the mouth. Patients should use MuGard 4 to 6 times daily, 5 mL of ready-to-use MuGard coats the oral cavity, and up to 10 mL can be used if needed.


Chemo Mouthpiece (Chemo Mouthpiece/Aurora BioScience)

Chemo Mouthpiece is a discreet, secure, and easy-to-use cryotherapy device that can effectively mitigate the debilitating effects of chemotherapy-induced oral mucositis. Chemo Mouthpiece builds upon an established treatment form, cryotherapy, which uses cold temperatures to improve the condition of the body. It is the same strategy that introduced ice chips and popsicles to hospitals and infusion centers. The device includes two chambers, a center core filled with filtered water, and an outer section filled with proprietary saline, which can reach freezing temperatures without solidifying. Two tubes run through the device so the patient can breathe comfortably. Chemo Mouthpiece can help battle the worst of the symptoms of oral mucositis by limiting the number of toxic chemicals that can interfere with the tissues of the cheeks, gums, tongue, lips, and palate.


Episil (Camurus)

Episil is a lipid-based fluid that transforms into a thin bioadhesive film when in contact with the buccal membrane, alleviating pain by protecting mucous membranes. In clinical trials, episil has been proven to reduce pain in the mouth by up to 40%, with a long-lasting effect of up to eight hours. The outstanding features of Episil are that it provides instant relief that is within five minutes post-application, in addition to this, it is convenient to consume food and drink within the same time only, and it acts as an effective oral pain relief lasting up to eight hours that comes handy with a ready-to-use, pocket-sized device.

Note: Detailed Current therapies assessment will be provided in the full report of OM


Oral Mucositis Emerging Drugs/Devices


Avasopasem/GC4419 (Galera Therapeutics)

Avasopasem, also known as avasopasem manganese or GC4419 is Galera’s lead product candidate. It is an investigational, highly selective small-molecule superoxide dismutase (SOD) mimetic that is being developed for the reduction of radiation-induced severe oral mucositis. Avasopasem manganese is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy.


SGX942 (Soligenix)

SGX942 (Dusquetide) is an investigational agent being developed by Soligenix, SGX942 is a rapid 4-minute infusion administered twice per week during chemotherapy and/or radiation treatment to reduce the duration and severity of severe oral mucositis. It is an intravenous formulation of the Innate Defense Regulator, dusquetide. Dusquetide is the active ingredient in SGX942, which is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis.


Cooral/CoolPrevent (BrainCool)

Cooral is a single-use oral cooling device that links to a portable cooling system and cools the oral mucosa. Cooral is equipped with an ECU200 water cooling unit that circulates 8°C water into an attached mouthpiece which is inserted into the patient’s mouth. The Cooral Device is a distinctive product and today has no rival in the market, as was verified by a very rapid patent approval. The product thus presents a 'breakthrough technology,' that is a revolutionary technology with a major clinical advantage over the drugs commercially available. It is noteworthy that CoolPrevent System is the only system available for the prevention of two of the most severe side effects of cancer treatment, oral mucositis, and neuropathy.


CareMin650 (NeoMedLight)

CareMin650 previously ONCORED from NeoMedLight is a device using the light-emitting fabric Lightex – unique patented technology – emitting light through woven optic fibres. It tackles the huge unmet clinical need for mucositis in cancer patients and reduces its societal, emotional, and economic burden. CareMin650’s operating mode is photobiomodulation, which uses the properties of specific light waves. Photobiomodulation, scientifically and clinically proven by numerous studies, is a complex biological mechanism of cell reparation that stimulates proliferation and migration of healthy cells.

Note: Detailed emerging therapies assessment will be provided in the final report.

Oral Mucositis Market Outlook

Currently, clinical management of oral mucositis is largely focused on palliative measures such as pain management, nutritional support, and maintenance of good oral hygiene. Recombinant human keratinocyte growth factor-1 (Palifermin) reduces the incidence of WHO grade 3 and 4 oral mucositis in patients with hematologic malignancies (e.g. lymphoma and multiple myeloma) receiving high-dose chemotherapy and total body irradiation before autologous hematopoietic cell transplantation. The US FDA has also approved Palifermin for patients with hematologic malignancies receiving myelotoxic therapies requiring hematopoietic cell support. The other treatment options may include interventions to reduce the mucosal toxicity of chemotherapy drugs, mouthwashes, immunomodulatory agents, topical anesthetics, mucosal barriers and coating agents, cytoprotectants.


Episil is a lipid-based fluid that transforms into a thin bioadhesive film when in contact with the buccal membrane, alleviating pain by protecting mucous membranes. Episil provides instant relief that is within five minutes post-application; it acts as an effective oral pain relief lasting up to 8 h that comes in handy with a ready-to-use, pocket-sized device. The device constitutes an oromucosal liquid in a multi-dose container and is without an active pharmaceutical ingredient. In addition to this, MuGard is a mucoadhesive oral wound rinse and is a viscous hydrogel polymer solution that is dispensed in a ready-to-use form. This device is supplied in plastic bottles and is intended for the treatment of oral wounds such as mucositis, stomatitis, traumatic ulcers, and aphthous ulcers. Apart from this, Chemo Mouthpiece is a discreet, secure, and easy-to-use cryotherapy device that can effectively mitigate the debilitating effects of chemotherapy-induced oral mucositis. Chemo Mouthpiece uses cold temperatures to improve the condition of the body. It is the same strategy that introduced ice chips and popsicles to hospitals and infusion centers. Kepivance (palifermin) is a truncated human keratinocyte growth factor (KGF) produced by recombinant DNA technology in E coli. It is a medicine indicated for the prevention and treatment of severe oral mucositis. It is used in patients with certain forms of blood cancer who are undergoing high-dose chemotherapy accompanied by a stem cell transplant and radiation therapy. Kepivance is a type of laboratory-made keratinocyte growth factor (KGF). KGF stimulates the growth of cells in the lining of the mouth, stomach, and gut. The candidate was approved in December 2004 by the US FDA making it the first therapy to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.


There is a high unmet need for new therapies for the treatment of oral mucositis. There are currently no FDA-approved drugs for the treatment of Oral Mucositis other than palifermin. Interventional strategies including coating agents, pain palliation, products, antiseptics, anti-inflammatories, and mouthwashes have little evidence supporting their effectiveness.


At present, some companies have indulged themselves in initiating clinical trials that investigate new treatment options. Key players such as Innovation Pharmaceuticals (Brilacidin), Enzychem Lifesciences Corporation (EC-18), NeoMedLight (CareMin650), Monopar Therapeutics (Validive), MuReva (Lumitex) (MuReva Phototherapy System), EpicentRx/Prothex Pharma (RRx-001), Soligenix (SGX942), Galera Therapeutics (GC4419), BrainCool (Cooral/CoolPrevent), and several others are investigating their candidates for the management of Oral Mucositis in the 7MM.


To summarize many potential therapies are being investigated for the management of Oral Mucositis, and it is safe to predict that the treatment space will experience a significant impact in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.

Note: Detailed Market Outlook will be provided in the final report.


Key Findings

The Oral Mucositis market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Oral Mucositis in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 6.4%. According to the estimates, the highest market size of Oral Mucositis is found in the United States followed by Japan and Germany.


The United States Oral Mucositis Market Outlook

The total market size of Oral Mucositis therapies in the United States is expected to increase in the study period (2018–2030) with a CAGR of 7.0%.


EU-5 Countries: Oral Mucositis Market Outlook

The total market size of Oral Mucositis therapies in the EU-5 countries is expected to increase in the study period (2018–2030) with a CAGR of 5.8%.


Japan Oral Mucositis Market Outlook

The total market size of Oral Mucositis therapies in Japan is expected to increase in the study period (2018–2030) with a CAGR of 4.9%.

Oral Mucositis Pipeline Development Activities

The drugs/devices which are in pipeline include:


1.Avasopasem/GC4419 (Galera Therapeutics)

2. SGX942 (Soligenix)

3. CareMin650 (NeoMedLight)

4. Cooral/CoolPrevent (BrainCool)

Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

Among emerging therapies, GC4419 from Galera Therapeutics, SGX942 from Soligenix, and Cooral system from BrainCool have the potential to disrupt the oral mucositis market. GC4419 and SGX942 are currently in phase III and targeting the head and neck cancer patients in their pivotal trial.


Growth of the oral mucositis market is expected to be mainly driven by increasing incidence of cancer cases, expected approval and readily penetration of emerging therapies, and an increase in Research and Development activities.


The high cost of treatment, little awareness about the disease, and lack of proper diagnostic methods are some of the factors which are expected to pose hurdles in the growth of the oral mucositis market.

Access and Reimbursement Scenario in OM Therapies

Oral Mucositis is a frequent complication of chemoradiation in head and neck cancer patients. Symptoms include painful and debilitating inflammation and ulceration, which increases a sufferer’s susceptibility to bacterial infections.


Fortovia offers the Fortovia Direct Rx Program, designed to facilitate access for all people who need the products, regardless of their insurance coverage, when fulfilled by a Fortovia Direct Rx specialty pharmacy. Fortovia Direct Rx Program offers:


  • Support across the portfolio of products, including Gelclair.
  • As little as USD 25 out-of-pocket costs for people who meet eligibility criteria.
  • A streamlined Patient Assistance Program for uninsured, underinsured, Medicare, Medicaid, and indigent patients
  • Free, 24-48 hour home delivery when ordered from a specialty pharmacy within the Fortovia Direct Rx network.


AMAG Pharmaceuticals launched patient reimbursement and support center for MuGard. Patients primarily received MuGard through specialty pharmacies, which received prescriptions from either MuGard patient reimbursement or support center, or the HUB, or physicians directly. HUB is a centralized patient intake and referral management center to process insurance coverage issues and administer our patient assistance and copayment programs. To provide MuGard to patients as soon as possible, the company has implemented a robust program that delivers a starter kit to clinicians, including a sample bottle and all pertinent information that the patient or caregiver needs to immediately begin MuGard therapy.

Note: Detailed Access and Reimbursement Scenario will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Oral Mucositis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Oral Mucositis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Oral Mucositis Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Oral Mucositis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Oral Mucositis epidemiology and treatment in the 7MM.
  • Additionally, an Oral Mucositis-inclusive account of both the current and emerging therapies for Oral Mucositis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Oral Mucositis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Oral Mucositis market.

Report Highlights

  • In the coming years, the Oral Mucositis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Oral Mucositis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Oral Mucositis. The launch of emerging therapies will significantly impact the Oral Mucositis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Oral Mucositis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Oral Mucositis Report Insights

  • Oral Mucositis Patient Population
  • Oral Mucositis Therapeutic Approaches
  • Oral Mucositis Pipeline Analysis
  • Oral Mucositis Market Size
  • Oral Mucositis Market Trends
  • Oral Mucositis Market Opportunities
  • Impact of upcoming Therapies

Oral Mucositis Report Key Strengths

  • 10 Years Forecast
  • Oral Mucositis 7MM Coverage
  • Oral Mucositis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Oral Mucositis Market
  • Oral Mucositis Drugs Uptake

Oral Mucositis Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Oral Mucositis Unmet Needs
  • Oral Mucositis Pipeline Product Profiles
  • Conjoint Analysis
  • Oral Mucositis Market Attractiveness
  • Oral Mucositis Market Drivers
  • Oral Mucositis Market Barriers

Key Questions

Oral Mucositis Market Insights:

  • What was the Oral Mucositis Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Oral Mucositis total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Oral Mucositis market size during the study period (2018–2030)?
  • At what CAGR, the Oral Mucositis market is expected to grow in the 7MM during the study period (2018–2030)?
  • What would be the Oral Mucositis market outlook across the 7MM during the study period (2018–2030)?
  • What would be the Oral Mucositis market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Oral Mucositis patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Oral Mucositis market?


Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of the Oral Mucositis?
  • What is the historical Oral Mucositis patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Oral Mucositis in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Oral Mucositis?
  • Out of all the 7MM countries, which country would have the highest incident population of Oral Mucositis during the study period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Oral Mucositis?


Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Oral Mucositis?
  • What are the current treatment guidelines for the treatment of Oral Mucositis in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Oral Mucositis?
  • How many therapies are developed by each company for the treatment of Oral Mucositis?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Oral Mucositis?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Oral Mucositis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Oral Mucositis and their status?
  • What are the key designations that have been granted for the emerging therapies for Oral Mucositis?
  • What is the global historical and forecasted market of Oral Mucositis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Oral Mucositis market.
  • To understand the future market competition in the Oral Mucositis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Oral Mucositis in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Oral Mucositis market.
  • To understand the future market competition in the Oral Mucositis market.

1. Key Insights

2. Executive Summary of Oral Mucositis

3. SWOT Analysis of Oral Mucositis

4. Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Oral Mucositis: Disease Background and Overview

6.1.  Introduction

6.1.1.  Signs and Symptoms of Oral Mucositis

6.1.2.  Risk Factors and Causes of Oral Mucositis

6.1.3.  Pathogenesis of Oral Mucositis

6.1.4.  Course of Oral Mucositis

6.1.5.  Genetics of Oral Mucositis

6.1.6.  Complications of Oral Mucositis

7. Diagnosis of Oral Mucositis

7.1.1.  Medical history for Oral Mucositis

7.1.2.  Grades of Oral Mucositis

8. Epidemiology and Patient Population

8.1.  Epidemiology Key Findings

8.2.  Assumptions and Rationale: 7MM

9. Epidemiology Scenario: 7MM

9.1.  Total Incident Cases of Oral Mucositis in the 7MM

9.2.  Grade-specific Incident Cases of Oral Mucositis in the 7MM

9.3.  Treated Cases of Oral Mucositis in the 7MM

10. The United States Epidemiology

10.1. Total Incident Cases of Oral Mucositis in the United States

10.2. Grade-specific Incident Cases of Oral Mucositis in the United States

10.3. Treated Cases of Oral Mucositis in the United States

11. EU-5 Epidemiology

11.1. Germany

11.1.1. Total Incident Cases of Oral Mucositis in Germany

11.1.2. Grade-specific Incident Cases of Oral Mucositis in Germany

11.1.3. Treated Cases of Oral Mucositis in Germany

11.2. France

11.2.1. Total Incident Cases of Oral Mucositis in France

11.2.2. Grade-specific Incident Cases of Oral Mucositis in France

11.2.3. Treated Cases of Oral Mucositis in France

11.3. Italy

11.3.1. Total Incident Cases of Oral Mucositis in Italy

11.3.2. Grade-specific Incident Cases of Oral Mucositis in Italy

11.3.3. Treated Cases of Oral Mucositis in Italy

11.4. Spain

11.4.1. Total Incident Cases of Oral Mucositis in Spain

11.4.2. Grade-specific Incident Cases of Oral Mucositis in Spain

11.4.3. Treated Cases of Oral Mucositis in Spain

11.5. The United Kingdom

11.5.1. Total Incident Cases of Oral Mucositis in the United Kingdom

11.5.2. Grade-specific Incident Cases of Oral Mucositis in the United Kingdom

11.5.3. Treated Cases of Oral Mucositis in the United Kingdom

11.6. Japan Epidemiology

11.6.1. Total Incident Cases of Oral Mucositis in Japan

11.6.2. Grade-specific Incident Cases of Oral Mucositis in Japan

11.6.3. Treated Cases of Oral Mucositis in Japan

12. Current Treatment Practices: Oral Mucositis

12.1. Treatment Algorithm of Oral Mucositis

12.1.1. Pain Control

12.1.2. Palliation of dry mouth

12.1.3. Nutritional Support

12.1.4. Oral Decontamination

12.1.5. Cryotherapy

12.1.6. Low-level laser therapy

12.1.7. Growth Factors

12.1.8. Antioxidants and Anti-inflammatory agents

13. Prevention of Oral Mucositis

14. Guidelines of Oral Mucositis

14.1. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

14.2. ESMO Clinical Practice Guidelines for Oral Mucositis (Modified from MASCC/ISOO Clinical Practice Guidelines for Oral Mucositis)

14.3. American Society of Clinical Oncology (ASCO) Guidelines for Oral Mucositis

14.4. National Comprehensive Cancer Network (NCCN) Task Force Recommendations for the Prevention and Management of Mucositis in Cancer Care

14.5. Pediatric Guidelines of NHS for Oral Mucositis

14.6. Mouth care guidance and support in cancer and palliative care - UK Oral Mucositis in Cancer Group

15. Unmet Needs

16. Patient Journey of Oral Mucositis

17. Key Endpoints in Oral Mucositis Clinical Trials

18. Marketed Therapies

18.1. Kepivance (Palifermin): Amgen/ Swedish Orphan Biovitrum

18.1.1. Product Description

18.1.2. Regulatory Milestones

18.1.3. Other Developmental Activities

18.1.4. Pivotal Clinical Trials

18.2. MuGard: Access Pharmaceuticals

18.2.1. Product Description

18.2.2. Regulatory Milestones

18.2.3. Other Developmental Activities

18.2.4. Pivotal Clinical Trials

18.3. Chemo Mouthpiece: Chemo Mouthpiece/ Aurora BioScience

18.3.1. Product Description

18.3.2. Pivotal Clinical Trial

18.3.3. Ongoing Current Pipeline Activity

18.4. Episil: Camurus

18.4.1. Product Description

18.4.2. Regulatory Milestones

18.4.3. Other Developmental Activities

18.4.4. Pivotal Clinical Trial

19. Emerging Therapies

19.1. Brilacidin: Innovation Pharmaceuticals

19.1.1. Product Description

19.1.2. Other Developmental Activities

19.1.3. Clinical Development

19.1.4. Safety and Efficacy

19.2. EC-18: Enzychem Lifesciences Corporation

19.2.1. Product Description

19.2.2. Other Developmental Activities

19.2.3. Clinical Developmental Activities

19.3. Cooral System: BrainCool

19.3.1. Product Description

19.3.2. Other Developmental Activities

19.3.3. Clinical Developmental Activities

19.3.4. Safety and Efficacy

19.4. CareMin650: NeoMedLight

19.4.1. Product Description

19.4.2. Other Developmental Activities

19.4.3. Clinical Developmental Activities

19.5. Validive (Clonidine Lauriad): Monopar Therapeutics

19.5.1. Product Description

19.5.2. Other Developmental Activities

19.5.3. Clinical Developmental Activities

19.5.4. Safety and Efficacy

19.6. MuReva Phototherapy System: MuReva (Lumitex)

19.6.1. Product Description

19.6.2. Other Developmental Activities

19.6.3. Clinical Developmental Activities

19.7. RRx-001: EpicentRx/Prothex Pharma

19.7.1. Product Description

19.7.2. Other Developmental Activities

19.7.3. Clinical Developmental Activities

19.7.4. Safety and Efficacy

19.8. SGX942: Soligenix

19.8.1. Product Description

19.8.2. Other Developmental Activities

19.8.3. Clinical Development

19.8.4. Safety and Efficacy

19.9. Avasopasem (GC4419): Galera Therapeutics

19.9.1. Product Description

19.9.2. Other Developmental Activities

19.9.3. Clinical Development

19.9.4. Safety and Efficacy

20. Oral Mucositis: Seven Major Market Analysis

20.1. Key Findings

20.2. Market Outlook: 7MM

21. 7MM Market Size

21.1. Total Market Size of Oral Mucositis in the 7MM

21.2. Total Market size of Oral Mucositis by Therapies in the 7MM

22. The United States Market Size

22.1. Total Market size of Oral Mucositis in the United States

23. EU-5 Market Size

23.1. Germany Market Size

23.1.1. Total Market size of Oral Mucositis in Germany

23.2. France Market Size

23.2.1. Total Market size of Oral Mucositis in France

23.3. Italy Market Size

23.3.1. Total Market size of Oral Mucositis in Italy

23.4. Spain Market Size

23.4.1. Total Market size of Oral Mucositis in Spain

23.5. The United Kingdom Market Size

23.5.1. Total Market size of Oral Mucositis in the United Kingdom

23.6. Japan Market Size

23.6.1. Total Market size of Oral Mucositis in Japan

24. Market Access and Reimbursement of Oral Mucositis Therapies

24.1. Patient Assistance Program

24.2. Reimbursement Management

25. Market Drivers of Oral Mucositis

26. Market Barriers of Oral Mucositis

27. Appendix

27.1. Bibliography

27.2. Report Methodology

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight

List of Table

Table 1: Summary of Oral Mucositis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Differential diagnosis of Oral Mucositis

Table 3: WHO oral mucositis scale/common toxicity criteria

Table 4: National Cancer Institute Common Terminology Crieria (NCI CTC) Grading of the severity of adverse events secondary to chemotherapy and radiotherapy toxicity.

Table 5: Radiation Therapy Oncology Group Scale

Table 6: Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer (RTOG/EORTC) Scale

Table 7: Oral assessment guide for children and young people

Table 8: Total Incident Cases of Oral Mucositis in the 7MM 2018–2030)

Table 9: Grade-specific Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Table 10: Total Treated Cases of Oral Mucositis in the 7MM (2018–2030)

Table 11: Total Incident Cases of Oral Mucositis in the United States (2018–2030)

Table 12: Grade-specific Incident Cases of Oral Mucositis in the United States (2018–2030)

Table 13: Treated Cases of Oral Mucositis in the United States (2018–2030)

Table 14: Total Incident Cases of Oral Mucositis in Germany (2018–2030)

Table 15: Grade-specific Incident Cases of Oral Mucositis in Germany (2018–2030)

Table 16: Treated Cases of Oral Mucositis in Germany (2018–2030)

Table 17: Total Incident Cases of Oral Mucositis in France (2018–2030)

Table 18: Grade-specific Incident Cases of Oral Mucositis in France (2018–2030)

Table 19: Treated Cases of Oral Mucositis in France (2018–2030)

Table 20: Total Incident Cases of Oral Mucositis in Italy (2018–2030)

Table 21: Grade-specific Incident Cases of Oral Mucositis in Italy (2018–2030)

Table 22: Treated Cases of Oral Mucositis in Italy (2018–2030)

Table 23: Total Incident Cases of Oral Mucositis in Spain (2018–2030)

Table 24: Grade-specific Incident Cases of Oral Mucositis in Spain (2018–2030)

Table 25: Treated Cases of Oral Mucositis in Spain (2018–2030)

Table 26: Total Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 27: Grade-specific Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 28: Treated Cases of Oral Mucositis in the United Kingdom (2018–2030)

Table 29: Total Incident Cases of Oral Mucositis in Japan (2018–2030)

Table 30: Grade-specific Incident Cases of Oral Mucositis in Japan (2018–230)

Table 31: Treated Cases of Oral Mucositis in Japan (2018–2030)

Table 32: Multinational Association of Supportive Care in Caner and International Society of Oral Oncology Clinical Practice Guidelines for Oral Mucositis

Table 33: ESMO Clinical Practice Guidelines

Table 34: Mouthcare for children and young people with cancer

Table 35: Routine recommended oral care

Table 36: Chemo Mouthpiece, Clinical Trial Description, 2021

Table 37: Brilacidin; Clinical Trial Description, 2021

Table 38: EC-18; Clinical Trial Description, 2021

Table 39: Cooral System; Clinical Trial Description, 2021

Table 40: CareMin650; Clinical Trial Description, 2021

Table 41: Validive (Clonidine Lauriad); Clinical Trial Description, 2021

Table 42: MuReva Phototherapy System; Clinical Trial Description, 2021

Table 43: RRx-001; Clinical Trial Description, 2021

Table 44: SGX942, Clinical Trial Description, 2021

Table 45: Avasopasem (GC4419), Clinical Trial Description, 2021

Table 46: 7MM Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 47: 7MM Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 48: The United States Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 49: The United States Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 50: Germany Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 51: Germany Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 52: France Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 53: France Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 54: Italy Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 55: Italy Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 56: Spain Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 57: Spain Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 58: The United Kingdom Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 59: The United Kingdom Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

Table 60: Japan Market Size of Oral Mucositis, in USD Million (2018–2030)

Table 61: Japan Market Size of Oral Mucositis by Therapies, in USD Million (2018–2030)

List of Figures

Figure 1: Oral Mucositis SWOT Analysis

Figure 2: Epidemiology and Market Methodology

Figure 3: Oral Mucositis

Figure 4: Signs and Symptoms

Figure 5: Risk factors of Oral Mucositis

Figure 6: Pathogenesis of Oral Mucositis

Figure 7: Cytokines responsible at different stages of Oral Mucositis

Figure 8: Severe oral ulcerations

Figure 9: Global Heat Map of All Cancers

Figure 10: Total Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 11: Grade-specific Incident Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 12: Treated Cases of Oral Mucositis in the 7MM (2018–2030)

Figure 13: Total Incident Cases of Oral Mucositis in the United States (2018–2030)

Figure 14: Grade-specific Incident Cases of Oral Mucositis in the United States (2018–2030)

Figure 15: Treated Cases of Oral Mucositis in the United States (2018–2030)

Figure 16: Total Incident Cases of Oral Mucositis in Germany (2018–2030)

Figure 17: Grade-specific Incident Cases of Oral Mucositis in Germany (2018–2030)

Figure 18: Treated Cases of Oral Mucositis in Germany (2018–2030)

Figure 19: Total Incident Cases of Oral Mucositis in France (2018–2030)

Figure 20: Grade-specific Incident Cases of Oral Mucositis in France (2018–2030)

Figure 21: Treated Cases of Oral Mucositis in France (2018–2030)

Figure 22: Total Incident Cases of Oral Mucositis in Italy (2018–2030)

Figure 23: Grade-specific Incident Cases of Oral Mucositis in Italy (2018–2030)

Figure 24: Treated Cases of Oral Mucositis in Italy (2018–2030)

Figure 25: Total Incident Cases of Oral Mucositis in Spain (2018–2030)

Figure 26: Grade-specific Incident Cases of Oral Mucositis in Spain (2018–2030)

Figure 27: Treated Cases of Oral Mucositis in Spain (2018–2030)

Figure 28: Total Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 29: Grade-specific Incident Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 30: Treated Cases of Oral Mucositis in the United Kingdom (2018–2030)

Figure 31: Total Incident Cases of Oral Mucositis in Japan (2018–2030)

Figure 32: Grade-specific Incident Cases of Oral Mucositis in Japan (2018–2030)

Figure 33: Treated Cases of Oral Mucositis in Japan (2018–2030)

Figure 34: Treatment Algorithm of Oral Mucositis

Figure 35: Approach to assessing risk of mucositis and prevention of oral mucositis

Figure 36: Unmet needs

Figure 37: Chemo Mouthpiece

Figure 38: Mechanism of EC-18

Figure 39: Mechanism of SGX942

Figure 40: Market Size of Oral Mucositis in the 7MM, in USD Million (2018–2030)

Figure 41: Market Size of Oral Mucositis in the 7MM by Therapy, in USD Million (2018–2030)

Figure 42: Total Market Size of Oral Mucositis in the United States, in USD Million (2018–2030)

Figure 43: Market Size of Oral Mucositis in the United States by Therapy, in USD Million (2018–2030)

Figure 44: Total Market Size of Oral Mucositis in Germany, in USD Million (2018–2030)

Figure 45: Market Size of Oral Mucositis in Germany by Therapies, in USD Million (2018–2030)

Figure 46: Total Market Size of Oral Mucositis in France, in USD Million (2018–2030)

Figure 47: Market Size of Oral Mucositis in France by therapies, in USD Million (2018–2030)

Figure 48: Total Market Size of Oral Mucositis in Italy, in USD Million (2018–2030)

Figure 49: Market Size of Oral Mucositis in Italy by Therapies, in USD Million (2018–2030)

Figure 50: Total Market Size of Oral Mucositis in Spain, in USD Million (2018–2030)

Figure 51: Market Size of Oral Mucositis in Spain by therapies, in USD Million (2018–2030)

Figure 52: Total Market Size of Oral Mucositis in the United Kingdom, in USD Million (2018–2030)

Figure 53: Market Size of Oral Mucositis in the United Kingdom by Therapies, in USD Million (2018–2030)

Figure 54: Total Market Size of Oral Mucositis in Japan, in USD Million (2018–2030)

Figure 55: Market Size of Oral Mucositis in Japan by Therapy, in USD Million (2018–2030)

Figure 56: Market Drivers

Figure 57: Market Barriers

Kepivance (Palifermin): Amgen/ Swedish Orphan Biovitrum

MuGard: Access Pharmaceuticals

Chemo Mouthpiece: Chemo Mouthpiece/ Aurora BioScience

Episil: Camurus

Brilacidin: Innovation Pharmaceuticals

EC-18: Enzychem Lifesciences Corporation

Cooral System: BrainCool

CareMin650: NeoMedLight

Validive (Clonidine Lauriad): Monopar Therapeutics

MuReva Phototherapy System: MuReva (Lumitex)

RRx-001: EpicentRx/Prothex Pharma

SGX942: Soligenix

  • Tags:
  • Oral Mucositis (OM) market
  • Oral Mucositis (OM) market researc...
  • Oral Mucositis (OM) market insight
  • Oral Mucositis (OM) market trends
  • Oral Mucositis (OM) market forecas...
  • Oral Mucositis (OM) market share
  • Oral Mucositis (OM) pipeline drugs
  • Oral Mucositis (OM) treatment algo...
  • Oral Mucositis (OM) drugs
  • Oral Mucositis (OM) sales forecast...
  • Oral Mucositis (OM) market size
  • Oral Mucositis (OM) disease
  • Oral Mucositis (OM) epidemiology
  • Oral Mucositis (OM)

Forward to Friend

Need A Quote